Immunotherapy for Microsatellite-Stable Metastatic Colorectal Cancer: Can we close the Gap between Potential and...

Area of Science:

• Oncology
• Immunotherapy
• Gastroenterology

Background:

• Colorectal cancer (CRC) is a leading global cancer.
• Metastatic CRC (mCRC) has limited treatment options.
• Immune checkpoint inhibitors (ICIs) are effective only in a subset of mCRC patients with microsatellite instability-high (MSI-H) tumors.

Purpose of the Study:

• To review strategies for overcoming ICI resistance in MSS mCRC.
• To identify potential biomarkers for patient selection.
• To discuss ongoing research in this field.

Main Methods:

• Literature review of current research on ICI therapy in mCRC.
• Analysis of studies investigating biomarkers for ICI response.
• Synthesis of data on novel therapeutic approaches for MSS mCRC.

Main Results:

• The majority of mCRC patients have MSS tumors and are resistant to ICIs.
• Current ICI efficacy in mCRC is primarily limited to MSI-H cases.
• Novel strategies are essential to enhance ICI effectiveness in MSS mCRC.

Conclusions:

• Developing effective treatments for MSS mCRC is a critical unmet need.
• Biomarker discovery is crucial for selecting patients who may benefit from novel therapies.
• Further research is required to improve ICI outcomes in MSS mCRC.